Periorbital Dermatology and Oculoplasty

  • Khaled El HoshyEmail author
  • Mona El-Kalioby


Dermatological disorders can be reflected in the eye and the periorbital area. Various skin diseases can affect the skin of the periorbital area e.g. dermatitis, vitiligo, xanthelasma, hidrocystomas, syringomas, milia, etc. Other cutaneous disorders may have associated ocular involvement e.g. rosacea, port-wine stain and nevus of Ota. Some infectious diseases can affect both the skin and eyes e.g. herpes simplex and herpes zoster. Systemic diseases can have ocular, as well as, dermatological involvement e.g. amyloidosis, dermatomyositis, sarcoidosis and Bechet’s disease. Periorbital dermatological procedures e.g. periorbital chemical peeling and laser procedures, and their expected complications, can be of interest to ophthalmologists.


Periorbital Periocular Eyebrows Eyelashes Eyelids 

Suggested Readings

  1. 1.
    Chopra K, Calva D, Sosin M, Tadisina KK, Banda A, De La Cruz C, et al. A comprehensive examination of topographic thickness of skin in the human face. Aesthetic Surg i [Internet]. 2015 Nov 27 [cited 2019 Mar 28];35(8):1007–13.
  2. 2.
    Stass-Isern M. Periorbital and orbital infantile hemangiomas. Int Ophthalmol Clin [Internet]. 2014 [cited 2019 Mar 29];54(3):73–82.
  3. 3.
    Xue L, Sun C, Xu D, Liu Z, Wang X-K. Clinical outcomes of infants with periorbital hemangiomas treated with oral propranolol. i Oral Maxillofac Surg [Internet]. 2016 Nov [cited 2019 Mar 29];74(11):2193–9.
  4. 4.
    Qiu Y, Ma G, Yang i, Hu X, Chen H, iin Y, et al. Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study. Clin Exp Dermatol [Internet]. 2013 Dec [cited 2019 Mar 29];38(8):845–50.
  5. 5.
    Hoornweg Mi, Saeed P, Tanck MWT, Hage ii, Coumou AD, Van Der Horst CMAM. Comparison of intralesional corticosteroid and propranolol treatment of periorbital infantile hemangiomas: an outcome study of 61 cases. Eur i Ophthalmol [Internet]. 2014 Nov 25 [cited 2019 Mar 29];24(6):940–7.
  6. 6.
    Waelchli R, Aylett SE, Robinson K, Chong WK, Martinez AE, Kinsler VA. New vascular classification of port-wine stains: improving prediction of Sturge-Weber risk. Br J Dermatol [Internet]. 2014 Oct [cited 2019 Mar 29];171(4):861–7.
  7. 7.
    Hagen SL, Grey KR, Korta DZ, Kelly KM. Quality of life in adults with facial port-wine stains. J Am Acad Dermatol [Internet]. 2017 Apr [cited 2019 Mar 29];76(4):695–702.
  8. 8.
    Chapas AM, Eickhorst K, Geronemus RG. Efficacy of early treatment of facial port wine stains in newborns: a review of 49 cases. Lasers Surg Med [Internet]. 2007 Aug [cited 2019 Mar 29];39(7):563–8.
  9. 9.
    Minkis K, Geronemus RG, Hale EK. Port wine stain progression: a potential consequence of delayed and inadequate treatment? Lasers Surg Med [Internet]. 2009 Aug [cited 2019 Mar 29];41(6):423–6.
  10. 10.
    Musalem HM, Alshaikh AA, Tuleimat LM, Alajlan S. Outcome with topical sirolimus for port wine stain malformations after unsatisfactory results with pulse dye laser treatment alone. Ann Saudi Med [Internet]. 2018 Sep [cited 2019 Mar 29];38(5):376–80.
  11. 11.
    Shah V V., Bray FN, Aldahan AS, Mlacker S, Nouri K. Lasers and nevus of Ota: a comprehensive review. Lasers Med Sci [Internet]. 2016 ian 12 [cited 2019 Mar 29];31(1):179–85.
  12. 12.
    Nam i-H, Kim H-S, Choi Yi, iung Hi, Kim W-S. Erratum: treatment and classification of nevus of Ota: a seven-year review of a single institution’s experience. Ann Dermatol [Internet]. 2017 [cited 2019 Mar 29];29(5):666.
  13. 13.
    Magarasevic L, Abazi Z. Unilateral open-angle glaucoma associated with the ipsilateral nevus of Ota. Case Rep Ophthalmol Med [Internet]. 2013 [cited 2019 Mar 29];2013:1–3.
  14. 14.
    Margulis A, Adler N, Bauer BS. Congenital melanocytic nevi of the eyelids and periorbital region. Plast Reconstr Surg [Internet]. 2009 Oct [cited 2019 Mar 29];124(4):1273–83.
  15. 15.
    Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol [Internet]. 2006 Jul [cited 2019 Mar 29];155(1):1–8.
  16. 16.
    Bray FN, Shah V, Nouri K. Laser treatment of congenital melanocytic nevi: a review of the literature. Lasers Med Sci [Internet]. 2016 Jan 12 [cited 2019 Mar 29];31(1):197–204.
  17. 17.
    Feser A, Mahler V. Periorbital dermatitis: causes, differential diagnoses and therapy. J der Dtsch Dermatologischen Gesellschaft [Internet]. 2009 Sep [cited 2019 Mar 28];
  18. 18.
    Feser A, Plaza T, Vogelgsang L, Mahler V. Periorbital dermatitis-a recalcitrant disease: causes and differential diagnoses. Br J Dermatol [Internet]. 2008 Oct [cited 2019 Mar 28];159(4):858–63.
  19. 19.
    Morris S, Barlow R, Selva D, Malhotra R. Allergic contact dermatitis: a case series and review for the ophthalmologist. Br J Ophthalmol [Internet]. 2011 Jul 1 [cited 2019 Mar 28];95(7):903–8.
  20. 20.
    Vakharia PP, Chopra R, Silverberg JI. Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials. Am J Clin Dermatol [Internet]. 2018 Feb 17 [cited 2019 Mar 28];19(1):15–22.
  21. 21.
    Jappe U, Schäfer T, Schnuch A, Uter W. Contact allergy in patients with rosacea: a clinic-based, prospective epidemiological study. J Eur Acad Dermatol Venereol [Internet]. 2008 Nov [cited 2019 Mar 28];22(10):1208–14.
  22. 22.
    Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol [Internet]. 2009 [cited 2019 Mar 28];10(2):103–18.
  23. 23.
    Wu MA, Perego F, Zanichelli A, Cicardi M. Angioedema phenotypes: disease expression and classification. Clin Rev Allergy Immunol [Internet]. 2016 Oct 26 [cited 2019 Mar 29];51(2):162–9.
  24. 24.
    Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy [Internet]. 2014 May [cited 2019 Mar 29];69(5):602–16.
  25. 25.
    Tay ET, Tsung JW. Sonographic appearance of angioedema in local allergic reactions to insect bites and stings. J Ultrasound Med [Internet]. 2014 Sep 1 [cited 2019 Mar 31];33(9):1705–10.
  26. 26.
    Redlick F, DeKoven J. Allergic contact dermatitis to paraphenylendiamine in hair dye after sensitization from black henna tattoos: a report of 6 cases. CMAJ [Internet]. 2007 Feb 13 [cited 2019 Mar 28];176(4):445–6.
  27. 27.
    Işik S, Caglayan-Sözmen S, Anal Ö, Karaman Ö, Uzuner N. Severe neck and face edema in an adolescent-delayed hypersensitivity reaction to hair dye. Pediatr Emerg Care [Internet]. 2017 Jun [cited 2019 Mar 28];33(6):422–3.
  28. 28.
    Tukenmez Demirci G, Kivanc Altunay I, Atis G, Kucukunal A. Allergic contact dermatitis mimicking angioedema due to paraphenylendiamine hypersensitivity: a case report. Cutan Ocul Toxicol [Internet]. 2012 Sep 19 [cited 2019 Mar 28];31(3):250–2.
  29. 29.
    van Genderen ME, Carels G, Lonnee ER, Dees A. Severe facial swelling in a pregnant woman after using hair dye. BMJ Case Rep [Internet]. 2014 Mar 31 [cited 2019 Mar 28];2014(mar31 1):bcr2013202562-bcr2013202562.
  30. 30.
    Williams K, Shinkai K. Evaluation and management of the patient with multiple syringomas: a systematic review of the literature. J Am Acad Dermatol [Internet]. 2016 Jun [cited 2019 Mar 29];74(6):1234–1240.e9.
  31. 31.
    Friedman SJ, Butler DF. Syringoma presenting as milia. J Am Acad Dermatol [Internet]. 1987 Feb [cited 2019 Mar 29];16(2 Pt 1):310–4.
  32. 32.
    Wang JI, Roenigk HH. Treatment of multiple facial syringomas with the carbon dioxide (CO2) laser. Dermatol Surg [Internet]. 1999 Feb [cited 2019 Mar 29];25(2):136–9.
  33. 33.
    Kitano Y. Erbium YAG laser treatment of periorbital syringomas by using the multiple ovoid-shape ablation method. J Cosmet Laser Ther [Internet]. 2016 Oct 3 [cited 2019 Mar 29];18(5):280–5.
  34. 34.
    Hasson A, Farias MM, Nicklas C, Navarrete C. Periorbital syringoma treated with radiofrequency and carbon dioxide (CO2) laser in 5 patients. J Drugs Dermatol [Internet]. 2012 Jul [cited 2019 Mar 29];11(7):879–80.
  35. 35.
    Karam P, Benedetto A V. Syringomas: new approach to an old technique. Int J Dermatol [Internet]. 1996 Mar [cited 2019 Mar 29];35(3):219–20.
  36. 36.
    Cho S Bin, Kim HJ, Noh S, Lee SJ, Kim YK, Lee JH. Treatment of syringoma using an ablative 10,600-nm carbon dioxide fractional laser: a prospective analysis of 35 patients. Dermatologic Surg [Internet]. 2011 Apr [cited 2019 Mar 29];37(4):433–8.
  37. 37.
    Roenigk HH. Dermabrasion for miscellaneous cutaneous lesions (exclusive of scarring from acne). J Dermatol Surg Oncol [Internet]. [cited 2019 Mar 29];3(3):322–8.
  38. 38.
    Frazier CC, Camacho AP, Cockerell CJ. The treatment of eruptive syringomas in an African American patient with a combination of trichloroacetic acid and CO2 laser destruction. Dermatol Surg [Internet]. 2001 May [cited 2019 Mar 29];27(5):489–92.
  39. 39.
    Seo H-M, Choi J-Y, Min J, Kim W-S. Carbon dioxide laser combined with botulinum toxin A for patients with periorbital syringomas. J Cosmet Laser Ther [Internet]. 2016 Jun 2 [cited 2019 Mar 29];18(3):149–53.
  40. 40.
    Moreno-González J, Rios-Arizpe S. A modified technique for excision of syringomas. J Dermatol Surg Oncol [Internet]. 1989 Aug [cited 2019 Mar 29];15(8):796–8.
  41. 41.
    Mainitz M, Schmidt JB, Gebhart W. Response of multiple syringomas to isotretinoin. Acta Derm Venereol [Internet]. 1986 [cited 2019 Mar 29];66(1):51–5.
  42. 42.
    Gómez MI, Pérez B, Azaña JM, Núñez M, Ledo A. Eruptive syringoma: treatment with topical tretinoin. Dermatology [Internet]. 1994 [cited 2019 Mar 29];189(1):105–6.
  43. 43.
    Sánchez TS, Daudén E, Casas AP, García-Díez A. Eruptive pruritic syringomas: treatment with topical atropine. J Am Acad Dermatol [Internet]. 2001 Jan [cited 2019 Mar 29];44(1):148–9.
  44. 44.
    Iwao F, Onozuka T, Kawashima T. Vulval syringoma successfully treated with tranilast. Br J Dermatol [Internet]. 2005 Dec [cited 2019 Mar 29];153(6):1228–30.
  45. 45.
    Horie K, Shinkuma S, Fujita Y, Ujiie H, Aoyagi S, Shimizu H. Efficacy of N-(3,4-imethoxycinnamoyl)-anthranilic acid (tranilast) against eruptive syringoma: report of two cases and review of published work. J Dermatol [Internet]. 2012 Dec [cited 2019 Mar 29];39(12):1044–6.
  46. 46.
    Alfadley A, Al Aboud K, Tulba A, Mourad MM. Multiple eccrine hidrocystomas of the face. Int J Dermatol [Internet]. 2001 Feb [cited 2019 Mar 29];40(2):125–9.
  47. 47.
    Sarabi K, Khachemoune A. Hidrocystomas—a brief review. MedGenMed [Internet]. 2006 Sep 6 [cited 2019 Mar 29];8(3):57.
  48. 48.
    Golden BA, Zide MF. Cutaneous cysts of the head and neck. J Oral Maxillofac Surg [Internet]. 2005 Nov [cited 2019 Mar 29];63(11):1613–9.
  49. 49.
    Ascherman JA, Knowles SL, Troutman KC. Extensive facial clefting in a patient with Goltz syndrome: multidisciplinary treatment of a previously unreported association. Cleft Palate Craniofac J [Internet]. 2002 Jul 15 [cited 2019 Mar 29];39(4):469–73.
  50. 50.
    Gira AK, Robertson D, Swerlick RA. Multiple eyelid cysts with palmoplantar hyperkeratosis—quiz case. Arch Dermatol [Internet]. 2004 Feb 1 [cited 2019 Mar 29];140(2):231–6.
  51. 51.
    Kim Y-D, Lee E-J, Song M-H, Suhr K-B, Lee J-H, Park J-K. Multiple eccrine hidrocystomas associated with Graves’ disease. Int J Dermatol [Internet]. 2002 May [cited 2019 Mar 29];41(5):295–7.
  52. 52.
    Gheisari M, Hamedani B, Robati R, Mozafari N. Intralesional botulinum toxin-A injection for the treatment of multiple eccrine hidrocystomas. J Cosmet Laser Ther [Internet]. 2018 Jul 4 [cited 2019 Mar 29];20(5):287–92.
  53. 53.
    Park HC, Kim EJ, Kim JE, Ro YS, Ko JY. Treatment of multiple eccrine hidrocystomas with isotretinoin followed by carbon dioxide laser. J Dermatol [Internet]. 2013 May [cited 2019 Mar 29];40(5):414–5.
  54. 54.
    Demirkan S. Treatment of multiple eccrine hidrocystoma with oral isotretinoin following erbium-yttrium aluminium garnet laser. J Cosmet Laser Ther [Internet]. 2019 Jan 2 [cited 2019 Mar 29];21(1):11–3.
  55. 55.
    Berk DR, Bayliss SJ. Milia: a review and classification. J Am Acad Dermatol [Internet]. 2008 Dec [cited 2019 Mar 29];59(6):1050–63.
  56. 56.
    Sachdeva M, Kaur S, Nagpal M, Dewan SP. Cutaneous lesions in new born. Indian J Dermatol Venereol Leprol [Internet]. [cited 2019 Mar 29];68(6):334–7.
  57. 57.
    Jouary T, Boralevi F, Meneguzzi G, Léautè-Labrèze C, Taïeb A. A disturbing milia eruption. Pediatr Dermatol [Internet]. [cited 2019 Mar 29];20(6):535–7.
  58. 58.
    Lee WS, Kim SJ, Ahn SK, Lee SH. Milia arising in herpes zoster scars. J Dermatol [Internet]. 1996 Aug [cited 2019 Mar 29];23(8):556–8.
  59. 59.
    Song JS, Kim NS, Kang WH. Grouped milia in an herpetiform arrangement following Stevens-Johnson syndrome [Internet]. 1998 [cited 2019 Mar 29].
  60. 60.
    Risma KA, Lucky AW. Pseudoacne of the nasal crease: a new entity? Pediatr Dermatol [Internet]. 2004 Jul [cited 2019 Mar 29];21(4):427–31.
  61. 61.
    George DE, Wasko CA, Hsu S. Surgical pearl: evacuation of milia with a paper clip. J Am Acad Dermatol [Internet]. 2006 Feb [cited 2019 Mar 29];54(2):326.
  62. 62.
    Higgins JC, Maher MH, Douglas MS. Diagnosing common benign skin tumors. Am Fam Physician [Internet]. 2015 Oct 1 [cited 2019 Mar 31];92(7):601–7.
  63. 63.
    $enel E, Salmanoglu M, Solmazgül E, Berçik Inal B. Acrochordons as a cutaneous sign of impaired carbohydrate metabolism, hyperlipidemia, liver enzyme abnormalities and hypertension: a case-control study. J Eur Acad Dermatology Venereol [Internet]. 2011 Dec 21 [cited 2019 Mar 31].
  64. 64.
    Metin SA, Lee BW, Lambert WC, Parish LC. Dermatosis papulosa nigra: a clinically and histopathologically distinct entity. Clin Dermatol [Internet]. 2017 Sep [cited 2019 Mar 31];35(5):491–6.
  65. 65.
    Garcia MS, Azari R, Eisen DB. Treatment of dermatosis Papulosa Nigra in 10 patients: a comparison trial of electrodesiccation, pulsed dye laser, and curettage. Dermatologic Surg [Internet]. 2010 Dec [cited 2019 Mar 31];36(12):1968–72.
  66. 66.
    Jain A, Goyal P, Nigam PK, Gurbaksh H, Sharma RC. Xanthelasma Palpebrarum-clinical and biochemical profile in a tertiary care hospital of Delhi. Indian J Clin Biochem [Internet]. 2007 Sep [cited 2019 Mar 29];22(2):151–3.
  67. 67.
    Gangopadadhya, Dey SK, Chanda M, Pal D, Chaudhuri S. Indian journal of dermatology. [Internet]. Indian J Dermatol. [publisher not identified]; 2019 [cited 2019 Mar 29];43:53 p.;year=1998;volume=43;issue=2;spage=53;epage=57;aulast=Gangopadadhya;type=0.
  68. 68.
    Esmat S, Abdel-Halim MRE, Fawzy MM, Nassef S, Esmat S, Ramzy T, et al. Are normolipidaemic patients with xanthelasma prone to atherosclerosis? Clin Exp Dermatol [Internet]. 2015 Jun [cited 2019 Mar 29];40(4):373–8.
  69. 69.
    Gladstone GJ, Beckman H, Elson LM. CO2 laser excision of xanthelasma lesions. Arch Ophthalmol (Chicago, Ill 1960) [Internet]. 1985 Mar [cited 2019 Mar 29];103(3):440–2.
  70. 70.
    Borelli C, Kaudewitz P. Xanthelasma palpebrarum: treatment with the erbium:YAG laser. Lasers Surg Med [Internet]. 2001 [cited 2019 Mar 29];29(3):260–4.
  71. 71.
    Nguyen AH, Vaudreuil AM, Huerter CJ. Systematic review of laser therapy in xanthelasma palpebrarum. Int J Dermatol [Internet]. 2017 Mar [cited 2019 Mar 29];56(3):e47–55.
  72. 72.
    Mourad B, Elgarhy LH, Ellakkawy H-A, Elmahdy N. Assessment of efficacy and tolerability of different concentrations of trichloroacetic acid vs. carbon dioxide laser in treatment of xanthelasma palpebrarum. J Cosmet Dermatol [Internet]. 2015 Sep [cited 2019 Mar 29];14(3):209–15.
  73. 73.
    Haygood LJ, Bennett JD, Brodell RT. Treatment of xanthelasma palpebrarum with bichloracetic acid. Dermatol Surg [Internet]. 1998 Sep [cited 2019 Apr 19];24(9):1027–31.
  74. 74.
    Rechichi M, Jaroudi MO, Meduri A, Scalinci SZ, Mazzotta C. Ectropion and Conjunctival Mass in a Patient with Primary Bilateral Conjunctival Amyloidosis. Case Rep Ophthalmol Med. 2016;2016:1–4.Google Scholar
  75. 75.
    Aryasit O, Preechawai P, Kayasut K. Clinical presentation, treatment, and prognosis of periocular and orbital amyloidosis in a university-based referral center. Clin Ophthalmol. 2013;7:801–5.Google Scholar
  76. 76.
    Forsyth CJ, Tiley CR. Raccoon eyes in systemic light chain amyloidosis. Med J Aust [Internet]. 2017 [cited 2019 Mar 29];206(9):384.
  77. 77.
    Kim J, Kim L, Kang SM. Primary Systemic Amyloidosis Involving the Lacrimal Sac. Korean J Ophthalmol [Internet]. 2016 Jun [cited 2019 Mar 29];30(3):234–5.
  78. 78.
    Vyas K, Morgaonkar M, Gupta S, Jain S. Primary systemic amyloidosis with unusual dermatological manifestations: A rare case report. Indian J Dermatol [Internet]. 2016 [cited 2019 Mar 29];61(2):216.
  79. 79.
    Bailey EE, Fiorentino DF. Amyopathic Dermatomyositis: Definitions, Diagnosis, and Management. Curr Rheumatol Rep [Internet]. 2014 Dec 4 [cited 2019 Mar 29];16(12):465.
  80. 80.
    Udkoff J, Cohen PR. Amyopathic dermatomyositis: a concise review of clinical manifestations and associated malignancies. Am J Clin Dermatol [Internet]. 2016 Oct 2 [cited 2019 Mar 29];17(5):509–18.
  81. 81.
    Mainetti C, Terziroli Beretta-Piccoli B, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol [Internet]. 2017 Dec 31 [cited 2019 Mar 29];53(3):337–56.
  82. 82.
    Santoro FA, Huang J. Ocular involvement in cutaneous connective tissue disease. Clin Dermatol [Internet]. 2016 Mar [cited 2019 Mar 29];34(2):138–45.
  83. 83.
    Strowd LC, Jorizzo JL. Review of dermatomyositis: establishing the diagnosis and treatment algorithm. J Dermatolog Treat [Internet]. 2013 Dec 25 [cited 2019 Mar 29];24(6):418–21.
  84. 84.
    Thomas KW, Hunninghake GW. Sarcoidosis. JAMA [Internet]. 2003 Jun 25 [cited 2019 Mar 29];289(24):3300.
  85. 85.
    Yang SJ, Salek S, Rosenbaum JT. Ocular sarcoidosis. Curr Opin Pulm Med [Internet]. 2017 Sep [cited 2019 Mar 29];23(5):458–67.
  86. 86.
    Ruocco E, Gambardella A, Langella GG, Lo Schiavo A, Ruocco V. Cutaneous sarcoidosis: an intriguing model of immune dysregulation. Int J Dermatol [Internet]. 2015 Jan [cited 2019 Mar 29];54(1):1–12.
  87. 87.
    Wanat KA, Rosenbach M. A practical approach to cutaneous sarcoidosis. Am J Clin Dermatol [Internet]. 2014 Aug 13 [cited 2019 Mar 29];15(4):283–97.
  88. 88.
    Sehgal VN, Riyaz N, Chatterjee K, Venkatash P, Sharma S. Sarcoidosis as a systemic disease. Clin Dermatol [Internet]. 2014 May 1 [cited 2019 Mar 29];32(3):351–63.
  89. 89.
    Musich PR, Li Z, Zou Y. Xeroderma Pigmentosa Group A (XPA), Nucleotide Excision Repair and Regulation by ATR in Response to Ultraviolet Irradiation. In 2017 [cited 2019 Mar 29]. p. 41–54.
  90. 90.
    Goyal JL, Rao VA, Srinivasan R, Agrawal K. Oculocutaneous manifestations in xeroderma pigmentosa. Br J Ophthalmol [Internet]. 1994 Apr [cited 2019 Mar 29];78(4):295–7.
  91. 91.
    Halkud R, Shenoy AM, Naik SM, Chavan P, Sidappa KT, Biswas S. Xeroderma Pigmentosum: clinicopathological review of the multiple oculocutaneous malignancies and complications. Indian J Surg Oncol [Internet]. 2014 Jun 9 [cited 2019 Mar 29];5(2):120–4.
  92. 92.
    McGrath JA. Lipoid proteinosis. In: Handbook of clinical neurology [Internet]. 2015 [cited 2019 Mar 29]. p. 317–22.
  93. 93.
    Di Giandomenico S, Masi R, Cassandrini D, El-Hachem M, De Vito R, Bruno C, et al. Lipoid proteinosis: case report and review of the literature. Acta Otorhinolaryngol Ital [Internet]. 2006 Jun [cited 2019 Mar 29];26(3):162–7.
  94. 94.
    Singh S, Mittal S, Bhari A, Bhari N. Lipoid proteinosis. BMJ Case Rep [Internet]. 2017 Oct 20 [cited 2019 Mar 29];2017:bcr-2017-221632.
  95. 95.
    Randle SC. Tuberous sclerosis complex: a review. Pediatr Ann [Internet]. 2017 Apr 1 [cited 2019 Mar 29];46(4):e166–71.
  96. 96.
    Krueger DA, Northrup H, Northrup H, Krueger DA, Roberds S, Smith K, et al. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol [Internet]. 2013 Oct [cited 2019 Mar 29];49(4):255–65.
  97. 97.
    Hodgson N, Kinori M, Goldbaum MH, Robbins SL. Ophthalmic manifestations of tuberous sclerosis: a review. Clin Experiment Ophthalmol [Internet]. 2017 Jan [cited 2019 Mar 29];45(1):81–6.
  98. 98.
    Anderson E, Fantus RJ, Haddadin RI. Diagnosis and management of herpes zoster ophthalmicus. Disease-a-Month [Internet]. 2017 Feb [cited 2019 Mar 28];63(2):38–44.
  99. 99.
    Borkar DS, Tham VM, Esterberg E, Ray KJ, Vinoya AC, Parker J V., et al. Incidence of herpes zoster ophthalmicus: results from the pacific ocular inflammation study. Ophthalmology [Internet]. 2013 Mar [cited 2019 Mar 28];120(3):451–6.
  100. 100.
    Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother [Internet]. 1995 Jul [cited 2019 Mar 28];39(7):1546–53.
  101. 101.
    Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. In: Han Y, editor. Cochrane database of systematic reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2013 [cited 2019 Mar 28].
  102. 102.
    Coplan PM, Schmader K, Nikas A, Chan ISF, Choo P, Levin MJ, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain [Internet]. 2004 Aug [cited 2019 Mar 28];5(6):344–56.
  103. 103.
    Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol [Internet]. 2007 Nov [cited 2019 Mar 28];57(5):737-63; quiz 764-6.
  104. 104.
    Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea [Internet]. 2001 Jan [cited 2019 Mar 28];20(1):1–13.
  105. 105.
    Summers BC, Margolis TP, Leib DA. Herpes simplex virus Type 1 corneal infection results in periocular disease by zosteriform spread. J Virol [Internet]. 2001 Jun 1 [cited 2019 Mar 28];75(11):5069–75.
  106. 106.
    Lio P. Warts, molluscum and things that go bump on the skin: a practical guide. Arch Dis Child Educ Pract Ed [Internet]. 2007 Aug 1 [cited 2019 Mar 28];92(4):ep119-24.
  107. 107.
    Ghadgepatil SS, Gupta S, Sharma YK. Clinicoepidemiological study of different types of warts. Dermatol Res Pract [Internet]. 2016 [cited 2019 Mar 28];2016:7989817.
  108. 108.
    Verma SB. Eyebrow threading: a popular hair-removal procedure and its seldom-discussed complications. Clin Exp Dermatol [Internet]. 2009 Apr [cited 2019 Mar 28];34(3):363–5.
  109. 109.
    Massing AM, Epstein WL. Natural history of warts. A two-year study. Arch Dermatol [Internet]. 1963 Mar [cited 2019 Mar 28];87:306–10.
  110. 110.
    Bacelieri R, Johnson SM. Cutaneous warts: an evidence-based approach to therapy. Am Fam Physician [Internet]. 2005 Aug 15 [cited 2019 Mar 28];72(4):647–52.
  111. 111.
    Kartal Durmazlar SP, Atacan D, Eskioglu F. Cantharidin treatment for recalcitrant facial flat warts: a preliminary study. J Dermatolog Treat [Internet]. 2009 Jan 12 [cited 2019 Mar 28];20(2):114–9.
  112. 112.
    Pollock B, Highet AS. An interesting response to diphencyprone (DPC) sensitization on facial warts: review of DPC treatment for viral warts. J Dermatolog Treat [Internet]. 2002 Jun 12 [cited 2019 Mar 28];13(2):47–50.
  113. 113.
    Senkevich TG, Bugert JJ, Sisler JR, Koonin E V, Darai G, Moss B. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science [Internet]. 1996 Aug 9 [cited 2019 Mar 28];273(5276):813–6.
  114. 114.
    Rosner M, Zloto O. Periocular molluscum contagiosum: six different clinical presentations. Acta Ophthalmol [Internet]. 2018 Aug [cited 2019 Mar 28];96(5):e600–5.
  115. 115.
    Gaurkar SP, Pund PB, Dindore PR, Bhoi UY. Extensive molluscum contagiosum causing obstruction of vision in HIV positive woman. Indian Dermatol Online J [Internet]. 2016 [cited 2019 Mar 28];7(3):190–1.
  116. 116.
    Ringeisen AL, Raven ML, Barney NP. Bulbar Conjunctival Molluscum Contagiosum. Ophthalmology [Internet]. 2016 Feb [cited 2019 Mar 28];123(2):294.
  117. 117.
    Yi JW, Li L, Luo DW. Phthiriasis palpebrarum misdiagnosed as allergic blepharoconjunctivitis in a 6-year-old girl. Niger J Clin Pract [Internet]. 2014 [cited 2019 Mar 28];17(4):537–9.
  118. 118.
    Lacarrubba F, Micali G. The Not-so-naked Eye: Phthiriasis Palpebrarum. Am J Med [Internet]. 2013 Nov [cited 2019 Mar 28];126(11):960–1.
  119. 119.
    Wu N, Zhang H, Sun FY. Phthiriasis palpebrarum: A case of eyelash infestation with Pthirus pubis. Exp Ther Med [Internet]. 2017 May [cited 2019 Mar 28];13(5):2000–2.
  120. 120.
    Pinckney J, Cole P, Vadapalli SP, Rosen T. Phthiriasis palpebrarum: a common culprit with uncommon presentation. Dermatol Online J [Internet]. 2008 Apr 15 [cited 2019 Mar 28];14(4):7.
  121. 121.
    Ngai JWS, Yuen HKL, Li FCH. An unusual case of eye itchiness. Hong Kong Med J = Xianggang yi xue za zhi [Internet]. 2008 Oct [cited 2019 Mar 28];14(5):414–5.
  122. 122.
    Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician [Internet]. 2014 Aug 15 [cited 2019 Mar 31];90(4):229–35.
  123. 123.
    Sarkar R, Ranjan R, Garg S, Garg VK, Sonthalia S, Bansal S. Periorbital hyperpigmentation: a comprehensive review. J Clin Aesthet Dermatol [Internet]. 2016 Jan [cited 2019 Mar 29];9(1):49–55.
  124. 124.
    Sheth P, Shah H, Dave J. Periorbital hyperpigmentation: A study of its prevalence, common causative factors and its association with personal habits and other disorders. Indian J Dermatol. 2014;59(2):151.Google Scholar
  125. 125.
    Roh MR, Chung KY. Infraorbital dark circles: Definition, causes, and treatment options. Dermatologic Surg. 2009;35(8):1163–71.Google Scholar
  126. 126.
    Kurban RS, Bhawan J. Histologic changes in skin associated with aging. J Dermatol Surg Oncol [Internet]. 1990 Oct [cited 2019 Mar 29];16(10):908–14.
  127. 127.
    Sodhi PK, Verma L, Ratan SK. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol [Internet]. 2004 Apr [cited 2019 Mar 30];137(4):783.
  128. 128.
    Doshi M, Edward DP, Osmanovic S. Clinical Course of Bimatoprost-Induced Periocular Skin Changes in Caucasians. Ophthalmology [Internet]. 2006 Nov [cited 2019 Mar 30];113(11):1961–7.
  129. 129.
    Ranu H, Thng S, Goh BK, Burger A, Goh CL. Periorbital hyperpigmentation in Asians: An epidemiologic study and a proposed classification. Dermatologic Surg. 2011;37(9):1297–303.Google Scholar
  130. 130.
    Gendler EC. Treatment of periorbital hyperpigmentation. Aesthetic Surg J. 2005;25(6):618–24.Google Scholar
  131. 131.
    Momosawa A, Kurita M, Ozaki M, Miyamoto S, Kobayashi Y, Ban I, et al. Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians. Plast Reconstr Surg. 2008;121(1):282–8.Google Scholar
  132. 132.
    Ranjan R, Sarkar R, Garg V, Gupta T. A comparative study of two modalities, 4% hydroquinone versus 30% salicylic acid in periorbital hyperpigmentation and assessment of quality of life before and after treatment. Indian J Dermatol. 2016;61(4):413.Google Scholar
  133. 133.
    Park SE, Kim SS, Kim CW, Her Y. A Prospective Split-Face Comparative Study of Periorbital Wrinkle Treatments: Fractional Erbium-Doped Yttrium Aluminum Garnet Laser, Intense Pulsed Light, and Topical 0.1% Tretinoin Cream. Ann Dermatol. 2016;28(5):650.Google Scholar
  134. 134.
    Lim JTE. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatologic Surg. 1999;25(4):282–4.Google Scholar
  135. 135.
    Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology. 2002;205(2–3):249–54.Google Scholar
  136. 136.
    Ertam I, Mutlu B, Unal I, Alper S, Kivçak B, Ozer O. Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol [Internet]. 2008 Sep [cited 2019 Mar 30];35(9):570–4.
  137. 137.
    Ohshima H, Mizukoshi K, Oyobikawa M, Matsumoto K, Takiwaki H, Kanto H, et al. Effects of vitamin C on dark circles of the lower eyelids: quantitative evaluation using image analysis and echogram. Skin Res Technol [Internet]. 2009 May [cited 2019 Mar 30];15(2):214–7.
  138. 138.
    Dayal S, Sahu P, Jain VK, Khetri S. Clinical efficacy and safety of 20% glycolic peel, 15% lactic peel, and topical 20% vitamin C in constitutional type of periorbital melanosis: a comparative study. J Cosmet Dermatol. 2016;15(4):367–73.Google Scholar
  139. 139.
    Karabudak O, Dogan B, Baloglu H. Histologic evidence of new collagen formation using a Q-switched Nd:YAG laser in periorbital rhytids. J Dermatolog Treat [Internet]. 2008 Jan 12 [cited 2019 Mar 30];19(5):300–4.
  140. 140.
    Tanzi EL, Williams CM, Alster TS. Treatment of facial rhytides with a nonablative 1,450-nm diode laser: a controlled clinical and histologic study. Dermatol Surg [Internet]. 2003 Feb [cited 2019 Mar 30];29(2):124–8.
  141. 141.
    Levy JL, Besson R, Mordon S. Determination of optimal parameters for laser for nonablative remodeling with a 1.54 microm Er:glass laser: a dose-response study. Dermatol Surg [Internet]. 2002 May [cited 2019 Mar 30];28(5):405–9.
  142. 142.
    Kontoes PP, Vlachos SP. Intense pulsed light is effective in treating pigmentary and vascular complications of CO(2) laser resurfacing. Aesthetic Surg J [Internet]. 2002 Sep [cited 2019 Mar 30];22(5):489–91.
  143. 143.
    Ahmed NA, Mohammed SS, Fatani MI. Treatment of periorbital dark circles: Comparative study of carboxy therapy vs chemical peeling vs mesotherapy. J Cosmet Dermatol. 2019;18(1):169–75.Google Scholar
  144. 144.
    Kontochristopoulos G, Kouris A, Platsidaki E, Markantoni V, Gerodimou M, Antoniou C. Combination of microneedling and 10% trichloroacetic acid peels in the management of infraorbital dark circles. J Cosmet Laser Ther [Internet]. 2016 Oct 3 [cited 2019 Mar 30];18(5):289–92.
  145. 145.
    Pascali M, Quarato D, Pagnoni M, Carinci F. Tear Trough Deformity: Study of Filling Procedures for Its Correction. J Craniofac Surg. 2017;28(8):2012–5.Google Scholar
  146. 146.
    Nofal E, Elkot R, Nofal A, Eldesoky F, Shehata S, Sami M. Evaluation of carboxytherapy and platelet-rich plasma in treatment of periorbital hyperpigmentation: A comparative clinical trial. J Cosmet Dermatol [Internet]. 2018 Dec 3 [cited 2019 Mar 30];17(6):1000–7.
  147. 147.
    Epstein JS. Management of infraorbital dark circles. A significant cosmetic concern. Arch Facial Plast Surg [Internet]. [cited 2019 Mar 30];1(4):303–7.
  148. 148.
    Paolo F, Nefer F, Paola P, Nicolò S. Periorbital area rejuvenation using carbon dioxide therapy. J Cosmet Dermatol. 2012;11(3):223–8.Google Scholar
  149. 149.
    Iannella G, Greco A, Didona D, Didona B, Granata G, Manno A, et al. Vitiligo: Pathogenesis, clinical variants and treatment approaches. Autoimmun Rev [Internet]. 2016 Apr [cited 2019 Mar 29];15(4):335–43.
  150. 150.
    Bulbul Baskan E, Baykara M, Ercan I, Tunali S, Yucel A. Vitiligo and ocular findings: a study on possible associations. J Eur Acad Dermatology Venereol [Internet]. 2006 Jul 3 [cited 2019 Mar 29]:060703142021002.
  151. 151.
    Sweet RD. Vitiligo as a Köbner phenomenon. Br J Dermatol [Internet]. 1978 Aug [cited 2019 Mar 29];99(2):223–4.
  152. 152.
    Jha AK, Sinha R, Prasad S, Nandan N. Bimatoprost in periorbital vitiligo: a ray of hope or dilemma. J Eur Acad Dermatology Venereol [Internet]. 2016 Jul [cited 2019 Mar 29];30(7):1247–8.
  153. 153.
    Speeckaert R, van Geel N. Vitiligo: An Update on Pathophysiology and Treatment Options. Am J Clin Dermatol [Internet]. 2017 Dec 2 [cited 2019 Mar 29];18(6):733–44.
  154. 154.
    Khong JJ, Casson RJ, Huilgol SC, Selva D. Madarosis. Surv Ophthalmol [Internet]. 2006 Nov [cited 2019 Mar 30];51(6):550–60.
  155. 155.
    Kumar A, Karthikeyan K. Madarosis: a marker of many maladies. Int J Trichology [Internet]. 2012 Jan [cited 2019 Mar 30];4(1):3–18.
  156. 156.
    Parrotta JN, Jones D, Meyer DR. Favre–Racouchot Disease of the Periocular Region. Ophthal Plast Reconstr Surg [Internet]. 2015 [cited 2019 Apr 20];31(4):e111–2.
  157. 157.
    Patterson WM, Fox MD, Schwartz RA. Favre-Racouchot disease. Int J Dermatol [Internet]. 2004 Mar 1 [cited 2019 Apr 20];43(3):167–9.
  158. 158.
    Paganelli A, Mandel VD, Kaleci S, Pellacani G, Rossi E. Favre-Racouchot disease: systematic review and possible therapeutic strategies. J Eur Acad Dermatology Venereol [Internet]. 2019 Jan 1 [cited 2019 Apr 20];33(1):32–41.
  159. 159.
    Kadhim KA, Al-Waiz M. Treatment of periorbital wrinkles by repeated medium-depth chemical peels in dark-skinned individuals. Vol. 4, Journal of Cosmetic Dermatology. 2009. p. 18–22.Google Scholar
  160. 160.
    Vavouli C, Katsambas A, Gregoriou S, Teodor A, Salavastru C, Alexandru A, et al. Chemical peeling with trichloroacetic acid and lactic acid for infraorbital dark circles. J Cosmet Dermatol. 2013;12(3):204–9.Google Scholar
  161. 161.
    Orra S, Waltzman JT, Mlynek K, Duraes EFR, Kundu N, Zins JE. Periorbital Phenol-Croton Oil Chemical Peel in Conjunction with Blepharoplasty. Plast Reconstr Surg [Internet]. 2015 Oct [cited 2019 Apr 21];136:99–100.
  162. 162.
    Sakhiya J, Nadkarni N, Patil S, Nikalji N, Godse K. Complications of medium depth and deep chemical peels. J Cutan Aesthet Surg. 2012;5(4):254.Google Scholar
  163. 163.
    Morrow DM. Chemical peeling of eyelids and periorbital area. J Dermatol Surg Oncol [Internet]. 1992 Feb [cited 2019 Mar 30];18(2):102–10.
  164. 164.
    Thach AB. Laser injuries of the eye. Int Ophthalmol Clin [Internet]. 1999 [cited 2019 Mar 30];39(2):13–27.
  165. 165.
    McKenzie AL. Aspects of laser safety in surgery and medicine. J Radiol Prot [Internet]. 1988 Dec 1 [cited 2019 Mar 30];8(4):209–19.
  166. 166.
    Ries WR, Clymer MA, Reinisch L. Laser safety features of eye shields. Lasers Surg Med [Internet]. 1996 [cited 2019 Mar 30];18(3):309–15.
  167. 167.
    Fife DJ, Fitzpatrick RE, Zachary CB. Complications of fractional CO2 laser resurfacing: Four cases. Lasers Surg Med. 2009;41(3):179–84.Google Scholar
  168. 168.
    Frankel J. Laser eyebrow epilation. Ophthalmology [Internet]. 2007 Mar [cited 2019 Mar 30];114(3):624.
  169. 169.
    Moreno-Arias GA, Casals-Andreu M, Camps-Fresneda A. Use of Q-switched alexandrite laser (755 nm, 100 nsec) for removal of traumatic tattoo of different origins. Lasers Surg Med [Internet]. 1999 [cited 2019 Mar 30];25(5):445–50.
  170. 170.
    Guedes R, Leite L. Removal of orange eyebrow tattoo in a single session with the Q-switched Nd:YAG 532-nm laser. Lasers Med Sci [Internet]. 2010 May 13 [cited 2019 Mar 30];25(3):465–6.
  171. 171.
    Radmanesh M, Rafiei Z. Combination of CO2 and Q-switched Nd:YAG lasers is more effective than Q-switched Nd:YAG laser alone for eyebrow tattoo removal. J Cosmet Laser Ther [Internet]. 2015 Apr 4 [cited 2019 Mar 30];17(2):65–8.
  172. 172.
    Yan L, Di L, Weihua W, Feng L, Ruilian L, Jun Z, et al. A study on the clinical characteristics of treating nevus of Ota by Q-switched Nd:YAG laser. Lasers Med Sci [Internet]. 2018 Jan 7 [cited 2019 Mar 30];33(1):89–93.
  173. 173.
    Kim YJ, Whang KU, Choi WB, Kim HJ, Hwang JY, Lee JH, et al. Efficacy and safety of 1,064 nm Q-switched Nd:yag laser treatment for removing melanocytic nevi. Ann Dermatol [Internet]. 2012 May [cited 2019 Mar 30];24(2):162.

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.School of MedicineCairo UniversityGizaEgypt

Personalised recommendations